Analysis
Medtronic faces significant financial headwinds from U.S. "Liberation Day" reciprocal tariffs introduced in April 2025. The company estimated a total net tariff impact of approximately $185M for fiscal year 2026, which primarily affects the cost of products sold (COGS). During the third quarter of 2026, the company recorded a specific impact of $93M, representing a 110 basis point headwind on adjusted gross margins. Management noted that the impact for the fourth quarter of 2026 is expected to be roughly $75M.
Looking ahead to fiscal year 2027, Medtronic expects the annual headwind to increase to approximately $300M as the full carryover effect of the tariffs takes hold. This estimate assumes a consistent quarterly impact of roughly $75M. The company's operating margin guidance for fiscal 2026 includes a roughly 50 basis point reduction attributable to these tariffs. Despite these costs, the company has maintained its expectation for high single-digit adjusted EPS growth in fiscal 2027, intending to offset tariff pressures through pricing, cost efficiency programs, and supply chain adjustments.
Medtronic's mitigation strategy involves rerouting products to optimize tariff exposure and adjusting its global supply chain. However, leadership has cautioned that shifting regulated medical device manufacturing is a multi-year process requiring extensive regulatory approvals at each site, limiting the company's ability to move production quickly. Additionally, the company noted a material impact on exports into the Chinese market, where trade barriers have hindered sales performance.
On February 20, 2026, the U.S. Supreme Court ruled that certain tariff policies under the International Emergency Economic Powers Act (IEEPA) were unconstitutional. While this ruling could potentially alleviate some of the projected headwinds, Medtronic's most recent financial reporting (dated February 24, 2026) continues to include the $185M and $300M estimates as it monitors the evolving legal and regulatory landscape. The company remains on an "offensive footing," prioritizing research and development and M&A to drive growth despite these macro challenges.
Data
| Metric | FY2026E | FY2027E |
|---|---|---|
| Estimated Net Tariff Cost (COGS) | $185.0 – $185.0 | $300.0 – $300.0 |
| Gross Margin Impact (bps) | 110bps | NA |
| Operating Margin Impact (bps) | 50bps | NA |
($M, except basis points. FY26-FY27 reflect company guidance as of February 2026.) Source: Quarterly Report 3Q-2026, Transcript 3Q-2026, Marvin Labs
Financial Impact
- Cost Impact (Historic): $185M
- Cost Impact (Forward-Looking): $300M
Sources
We anticipate a tariff impact to COGS of approximately $185mn, including $75mn in the Q4. Including tariffs, we expect fiscal 2026 gross margin decrease of roughly 30 basis points. Our fiscal 2026 operating margin is expected to be... down about 50 basis points, including the tariff impact.
We will have the carryover from the tariffs, the tariff settlement, going into next year. You know, this year we had about 2.5 quarters of tariffs, and that will carry over into the full year. I think the way to think about that is about $75mn per quarter. So on a full year basis, it means around $300mn of headwind versus the $185 we had in... 2026.
Based on current rates as of February 17, 2026, we estimate the pre-tax net tariff impact to be $185 million in fiscal year 2026... Further escalation or expansion of trade barriers could have a material adverse effect on our results of operations. On February 20, 2026, the U.S. Supreme Court ruled that President Trump's tariff policies under the International Emergency Economic Powers Act are unconstitutional.